tipifarnib has been researched along with losartan potassium in 3 studies
Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (losartan potassium) | Trials (losartan potassium) | Recent Studies (post-2010) (losartan potassium) |
---|---|---|---|---|---|
309 | 92 | 94 | 24,390 | 2,493 | 5,408 |
Protein | Taxonomy | tipifarnib (IC50) | losartan potassium (IC50) |
---|---|---|---|
Bile salt export pump | Homo sapiens (human) | 8.53 | |
Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0049 | |
Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.0082 | |
Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gabrilove, JL | 1 |
Cassinat, B; Chomienne, C; Gervais, N; Larghero, J; Padua, RA; Rain, JD; Rousselot, P; Schlageter, MH | 1 |
Odenike, O; Tefferi, A | 1 |
2 review(s) available for tipifarnib and losartan potassium
Article | Year |
---|---|
Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes.
Topics: Alkyl and Aryl Transferases; Anemia; Enzyme Inhibitors; Erythropoietin; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Recombinant Proteins | 2001 |
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins | 2005 |
1 other study(ies) available for tipifarnib and losartan potassium
Article | Year |
---|---|
Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.
Topics: Alkyl and Aryl Transferases; Case-Control Studies; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Farnesyltranstransferase; Humans; Polycythemia Vera; Quinolones | 2005 |